| 1. |
-
- 2019
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
- Du-Bar, Christian, et al.
(författare)
-
Comparison of Performance and Manufacturing Aspects of an Insert Winding and a Hairpin Winding for an Automotive Machine Application
- 2018
-
Ingår i: 2018 8th International Electric Drives Production Conference, EDPC 2018 - Proceedings. - : Institute of Electrical and Electronics Engineers Inc.. - 9781728101477
-
Konferensbidrag (refereegranskat)abstract
- In this paper, two stators with different winding concepts but with the same rotor of an interior permanent magnet synchronous machine (IPMSM) type are presented. Both concepts are investigated based on their performance and their respectively stator cost and stator manufacturing aspects for a yearly production rate of 1 million units.
|
|
| 3. |
- Cencetti, Michele, et al.
(författare)
-
CROSS DRIVE: A Collaborative Virtual Reality Workplace for Space Science Data Exploitation and Rover Operations Engineering
- 2016
-
Ingår i: SECESA 2016.
-
Konferensbidrag (refereegranskat)abstract
- The CrossDrive Project develops Distributed and Collaborative Infrastructure based on advanced Immersive Virtual Reality tools for the analysis and management of Scientific Data and Operational Activities of planetary spacecraft. The Collaborative Workspace encompasses advanced technological solutions for central storage processing, 3D visualisation and Virtual Presence in Immersive Virtual Reality environments, to support Space Data Analysis and Space Operations. Science objectives are share and correlate Atmospheric data, analysis and simulations based on the actual main Mars’ satellites (MEX and MRO); compare and correlate data for Geology and Geodesy; benchmark satellite and ground based Mars atmospheric measurements.
|
|
| 4. |
- Engelke, Wito, 1983-, et al.
(författare)
-
Scientific Visualization for Atmospheric Data Analysis in Collaborative Virtual Environments
- 2016
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- The three year European research project CROSS DRIVE (Collaborative Rover Operations and Planetary Science Analysis System based on Distributed Remote and Interactive Virtual Environments) started in January 2014. The research and development within this project is motivated by three use case studies: landing site characterization, atmospheric science and rover target selection.Currently the implementation for the second use case is in its final phase. Here, the requirements were generated based on the domain experts input and lead to development and integration of appropriate methods for visualization and analysis of atmospheric data. The methods range from volume rendering, interactive slicing, iso-surface techniques to interactive probing. All visualization methods are integrated in DLR’s Terrain Rendering application. With this, the high resolution surface data visualization can be enriched with additional methods appropriate for atmospheric data sets. This results in an integrated virtual environment where the scientist has the possibility to interactively explore his data sets directly within the correct context. The data sets include volumetric data of the martian atmosphere, precomputed two dimensional maps and vertical profiles. In most cases the surface data as well as the atmospheric data has global coverage and is of time dependent nature. Furthermore, all interaction is synchronized between different connected application instances, allowing for collaborative sessions between distant experts.
|
|
| 5. |
- Engelke, Wito, 1983-, et al.
(författare)
-
Scientific Visualization for Space Science Data Analysis in Collaborative Virtual Environments
- 2015
-
Ingår i: Proceedings of IEEE SciVis 2015. - : Institute of Electrical and Electronics Engineers (IEEE).
-
Konferensbidrag (refereegranskat)abstract
- The European research project CROSS DRIVE (Collaborative Rover Operations and Planetary Science Analysis System based on Distributed Remote and Interactive Virtual Environments) aims at developing an innovative collaborative workspace infrastructure enabling re- mote scientific and engineering experts to collectively analyze and interpret combined datasets using shared simulation tools. The three year project started in January 2014 and unites best European expertise in the fields of planetary research and Mars science, Virtual Reality (VR), atmospheric science and research as well as rover mission planning.
|
|
| 6. |
- Garcia, Arturo S., et al.
(författare)
-
A collaborative workspace architecture for strengthening collaboration among space scientists
- 2015
-
Ingår i: Proceedings of a meeting held 7-14 March 2015, Big Sky, Montana, USA.. - : Institute of Electrical and Electronics Engineers (IEEE). - 9781479953790 - 9781479953806 - 9781479953776 ; , s. 1133-1144
-
Konferensbidrag (refereegranskat)abstract
- Space exploration missions have produced large data of immense value, to both research and the planning and operating of future missions. However, current datasets and simulation tools fragment teamwork, especially across disciplines and geographical location. The aerospace community already exploits virtual reality for purposes including space tele-robotics, interactive 3D visualization, simulation and training. However, collaborative virtual environments are yet to be widely deployed or routinely used in space projects. Advanced immersive and collaborative visualization systems have the potential for enhancing the efficiency and efficacy of data analysis, simplifying visual benchmarking, presentations and discussions. We present preliminary results of the EU funded international project CROSS DRIVE, which develops an infrastructure for collaborative workspaces for space science and missions. The aim is to allow remote scientific and engineering experts to collectively analyze and interpret combined datasets using shared simulation tools. The approach is to combine advanced 3D visualization techniques and interactive tools in conjunction with immersive virtuality telepresence. This will give scientists and engineers the impression of teleportation from their respective buildings across Europe, to stand together on a planetary surface, surrounded by the information and tools that they need. The conceptual architecture and proposed realization of the collaborative workspace are described. ESA's planned ExoMars mission provides the use-case for deriving user requirements and evaluating our implementation.
|
|
| 7. |
- Hindricks, Gerhard, et al.
(författare)
-
Ability to remotely monitor atrial high-rate episodes using a single-chamber implantable cardioverter-defibrillator with a floating atrial sensing dipole
- 2023
-
Ingår i: Europace. - : Oxford University Press. - 1099-5129 .- 1532-2092. ; 25:5
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: To allow timely initiation of anticoagulation therapy for the prevention of stroke, the European guidelines on atrial fibrillation (AF) recommend remote monitoring (RM) of device-detected atrial high-rate episodes (AHREs) and progression of arrhythmia duration along pre-specified strata (6 min...<1h, 1 h...<24 h, >= 24h). We used the MATRIX registry data to assess the capability of a single-lead implantable cardioverter-defibrillator (ICD) with atrial sensing dipole (DX ICD system) to follow this recommendation in patients with standard indication for single-chamber ICD.Methods and results: In 1841 DX ICD patients with daily automatic RM transmissions, electrograms of first device-detected AHREs per patient in each duration stratum were adjudicated, and the corresponding positive predictive values (PPVs) for the detections to be true atrial arrhythmia were calculated. Moreover, the incidence and progression of new-onset AF was assessed in 1451 patients with no AF history. A total of 610 AHREs >= 6min were adjudicated. The PPV was 95.1% (271 of 285) for episodes 6min...<1h, 99.6% (253/254) for episodes 1 h...<24h, 100% (71/71) for episodes >= 24h, or 97.5% for all episodes (595/610). The incidence of new-onset AF was 8.2% (119/1451), and in 31.1% of them (37/119), new-onset AF progressed to a higher duration stratum. Nearly 80% of new-onset AF patients had high CHA(2)DS(2)-VASc stroke risk, and 70% were not on anticoagulation therapy. Age was the only significant predictor of new-onset AF.Conclusion: A 99.7% detection accuracy for AHRE >= 1h in patients with DX ICD systems in combination with daily RM allows a reliable guideline-recommended screening for subclinical AF and monitoring of AF-duration progression.
|
|
| 8. |
- Kappos, Ludwig, et al.
(författare)
-
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- 2018
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 391, s. 1263-1273
-
Tidskriftsartikel (refereegranskat)abstract
- © 2018 Elsevier Ltd Background: No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor 1,5 modulator, on disability progression in patients with SPMS. Methods: This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospital clinics and specialised multiple sclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatme nt arms, patients (age 18–60 years) with SPMS and an Expanded Disability Status Scale score of 3·0–6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time to 3-month CDP. Efficacy was assessed for the full analysis set (ie, all randomly assigned and treated patients); safety was assessed for the safety set. This trial is registered with ClinicalTrials.gov, number NCT01665144. Findings: 1651 patients were randomly assigned between Feb 5, 2013, and June 2, 2015 (1105 to the siponimod group, and 546 to the placebo group). One patient did not sign the consent form, and five patients did not receive study drug, all of whom were in the siponimod group. 1645 patients were included in the analyses (1099 in the siponimod group and 546 in the placebo). At baseline, the mean time since first multiple sclerosis symptoms was 16·8 years (SD 8·3), and the mean time since conversion to SPMS was 3·8 years (SD 3·5); 1055 (64%) patients had not relapsed in the previous 2 years, and 918 (56%) of 1651 needed walking assistance. 903 (82%) patients receiving siponimod and 424 (78%) patients receiving placebo completed the study. 288 (26%) of 1096 patients receiving siponimod and 173 (32%) of 545 patients receiving placebo had 3-month CDP (hazard ratio 0·79, 95% CI 0·65–0·95; relative risk reduction 21%; p=0·013). Adverse events occurred in 975 (89%) of 1099 patients receiving siponimod versus 445 (82%) of 546 patients receiving placebo; serious adverse events were reported for 197 (18%) patients in the siponimod group versus 83 (15%) patients in the placebo group. Lymphopenia, increased liver transaminase concentration, bradycardia and bradyarrhythmia at treatment initiation, macular oedema, hypertension, varicella zoster reactivation, and convulsions occurred more frequently with siponimod than with placebo. Initial dose titration mitigated cardiac first-dose effects. Frequencies of infections, malignancies, and fatalities did not differ between groups. Interpretation: Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS. Funding: Novartis Pharma AG.
|
|
| 9. |
|
|
